Advancements in CAR-T therapy show promise in treating multiple myeloma and blood cancers.
TL;DR Summary
J&J and Legend Biotech's CAR-T therapy, Carvykti, showed a 74% reduction in the risk of disease progression or death for adults with multiple myeloma who had received between one and three previous treatments. However, it remains to be seen how many patients will take the therapy and when it will become widely available.
- J&J takes victory lap on its Carvykti data. But how many patients will take it — and when? #ASCO23 Endpoints News
- Genetically modifying T-cells cuts blood cancer progression by 74%, trial finds The Guardian
- ASCO: J&J, Legend's Carvykti stages stellar show in earlier myeloma. But has the CAR-T reached a ceiling? FiercePharma
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma | NEJM nejm.org
- Breakthrough in treating one of the deadliest cancers Daily Mail
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
58%
125 → 53 words
Want the full story? Read the original article
Read on Endpoints News